14 peptides are returning to legal compounding status
The 2026 RFK reclassification is expected to reverse the FDA's 2023 Category 2 designation for 14 widely used peptides. Once complete, licensed compounding pharmacies will be able to produce these compounds with a valid prescription — no gray market needed.
What does reclassification mean?
Under the FDA's 2023 final rule, these 14 peptides were classified as Category 2 bulk drug substances — meaning they could not be legally compounded by 503A or 503B pharmacies, even with a valid prescription.
The reclassification moves them back to Category 1, which means licensed compounding pharmacies can legally produce them again. This is significant because it creates a legal, prescription-based path to access peptides that have been available only through unregulated gray market vendors.
For consumers, this means pharmaceutical-grade peptides from inspected, licensed facilities — with proper dosing, sterility testing, and physician oversight.
Reclassification timeline
Secretary Kennedy announced the intent to reclassify 14 peptides from Category 2 to Category 1, reversing the FDA's 2023 final rule.
The FDA must publish a proposed rule in the Federal Register, opening a public comment period before any reclassification can take effect.
After reviewing public comments, the FDA publishes the final rule. Category 1 status would allow 503A and 503B pharmacies to compound these peptides with a valid prescription.
Licensed pharmacies with USP compliance and proper registrations can begin compounding. Availability timeline will vary by pharmacy and peptide.
The 14 peptides
These peptides are expected to return to legal compounding status once FDA rulemaking is finalized.
BPC-157
Body Protection Compound
Tissue repair & gut health
One of the most widely used peptides in the research market. Known for gut healing and tissue repair applications.
TB-500
Thymosin Beta-4 fragment
Tissue repair & recovery
Used for wound healing, tissue repair, and recovery from injury. Often paired with BPC-157.
Thymosin Alpha-1
Ta1
Immune modulation
Immune-modulating peptide approved as a drug in over 30 countries outside the US.
CJC-1295
with/without DAC
Growth hormone secretagogue
Growth hormone releasing hormone analog. Often combined with Ipamorelin.
Ipamorelin
Growth hormone secretagogue
Selective GH secretagogue with fewer side effects than other GHRPs. Common in anti-aging protocols.
GHK-Cu
Copper peptide
Skin & tissue regeneration
Copper-binding peptide with applications in skin health, wound healing, and hair growth.
AOD-9604
Anti-Obesity Drug fragment
Metabolic / fat loss
Modified fragment of human growth hormone targeting fat metabolism without GH side effects.
Selank
Nootropic / anxiolytic
Synthetic analog of tuftsin. Used for anxiety reduction and cognitive enhancement. Approved in Russia.
Semax
Nootropic / neuroprotective
Synthetic analog of ACTH. Used for cognitive enhancement, stroke recovery, and neuroprotection. Approved in Russia.
Epithalon
Epitalon
Anti-aging / telomerase
Synthetic tetrapeptide based on epithalamin. Research focuses on telomerase activation and longevity.
DSIP
Delta Sleep-Inducing Peptide
Sleep & recovery
Naturally occurring neuropeptide studied for its role in sleep regulation and stress response.
PT-141
Bremelanotide
Sexual health
Melanocortin receptor agonist. FDA-approved as Vyleesi for HSDD; compounding expands access to other formulations.
Kisspeptin-10
Hormonal / reproductive
Key regulator of reproductive hormones. Research applications in fertility and hormonal balance.
MOTS-c
Metabolic / exercise mimetic
Mitochondrial-derived peptide with exercise-mimetic properties. Studied for metabolic health and longevity.
What hasn't changed yet
The February 2026 announcement is not yet law. Formal FDA rulemaking (proposed rule, comment period, final rule) is still required.
Until the final rule is published, these 14 peptides remain Category 2. Compounding pharmacies cannot legally produce them today.
Even after reclassification, compounded peptides require a valid prescription from a licensed provider. This is not over-the-counter access.
Research-use-only vendors continue to operate in the same regulatory gray area. Reclassification specifically affects compounding pharmacies.
Get notified when legal peptide access launches
Valitide is building a telehealth platform to connect patients with licensed compounding pharmacies for prescription peptide access. Join the waitlist to be first in line.
No spam. We'll only email you when there's a real regulatory update or when the platform launches.